Related Experiment Video
Updated: May 16, 2026

10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Targeting dendritic cells in situ for breast cancer immunotherapy
1Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease; The Rockefeller University; New York, NY USA.
Oncoimmunology
|December 18, 2012
Abstract:
We have recently developed a protein vaccine against breast cancer in which HER2 is delivered to dendritic cells (DCs) in vivo through receptors expressed on their surface. Our results indicate that this is a promising approach to induce durable, broad and integrated immunity against breast cancer.

